CIITA Antibody
| Code | Size | Price |
|---|
| PSI-5979-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5979-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
CIITA Antibody: C2TA, NLRA, MHC2TA, CIITAIV, MHC class II transactivator, CIITA
Application Note:
CIITA antibody can be used for detection of CIITA by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
CIITA Antibody: CIITA contains an acidic transcriptional activation domain, four LRRs (leucine-rich repeats) and a GTP binding domain. It is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. CIITA also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction.
Background References:
- LeibundGut-Landmann S, Waldburger JM, Krawczyk M, et al. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 2004; 34:1513-25.
- Harton JA, Cressman DE, Chin KC, et al. GTP binding by class II transactivator: role in nuclear import. Science 1999; 285:1402-5.
- Raval A, Howcroft TK, Weissman JD, et al. Transcriptional coactivator, CIITA, is an acetyltransferase that bypasses a promoter requirement for TAF(II)250. Mol. Cell 2001; 7:105-15.
- Inohara C, McDonald C, and Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu. Rev. Biochem. 2005; 74:355-83.
Buffer:
CIITA Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
CIITA antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human CIITA.
The immunogen is located within amino acids 120 - 170 of CIITA.
The immunogen is located within amino acids 120 - 170 of CIITA.
NCBI Gene ID #:
4261
NCBI Official Name:
class II, major histocompatibility complex, transactivator
NCBI Official Symbol:
CIITA
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 124 kDa
Observed: 125 kDa
Observed: 125 kDa
Protein Accession #:
P33076
Protein GI Number:
218511957
Purification:
CIITA Antibody is affinity chromatography purified via peptide column.
Research Area:
Immunology
Swissprot #:
P33076
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | CIITA Peptide | PSI-5979P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|